



Latest Developments

- Medical Cannabis (June 2024 – June 2025)

*Dr Alan Cross
16 June 2025
Neurohaven*

Latest Developments - Medical Cannabis (June 2024 – June 2025)

Medical Research and Clinical Applications

Mental Health (PTSD, Anxiety, Depression):

Significant progress was made in exploring cannabis for PTSD and related conditions. In late 2024, the U.S. FDA greenlit a large multi-state trial (MJP2) to test high-THC cannabis for post-traumatic stress disorder in veterans psychiatrist.com/psychiatrist.com. This study allows participants to **self-titrate** inhaled cannabis doses (mimicking real-world use) and aims to provide rigorous data on safety and efficacy for PTSD relief psychiatrist.com/psychiatrist.com.

Separately, an observational UK study reported that prescribed **cannabis-based medicines** led to “substantial reductions” in PTSD symptoms (with even greater improvement in patients with comorbid depression) after three months of therapy norml.org. Early clinical research has also expanded beyond THC and CBD – for example, the first human trial of **cannabigerol (CBG)** in 2024 found that a 20 mg dose **significantly reduced anxiety and stress** levels in participants, without any cognitive impairment marijuanamoment.net. These findings highlight cannabis’s potential to improve mental health outcomes such as PTSD-related anxiety and mood, though more controlled trials are ongoing.

Chronic Pain Management:

Medical cannabis continued to gain support as an adjunct or alternative for chronic pain. A May 2025 study of 129 chronic pain patients in Pennsylvania found that **over 80%** of those using medical marijuana reported effective pain relief marijuanamoment.net. Researchers noted cannabis could serve as a “safer alternative or complement to standard pain management”, potentially reducing reliance on opioids marijuanamoment.net. Survey data showed high patient satisfaction: 93% agreed cannabis improved their primary symptoms marijuanamoment.net, and many also reported better sleep and less anxiety with use marijuanamoment.net.

Notably, **topical formulations** were the most popular administration method among these patients (used by ~63%, often alongside oils or edibles) marijuanamoment.net. Emerging evidence suggests cannabis may indeed help address the opioid crisis; for example, an analysis by University of Pittsburgh and Harvard researchers found that supervised medical marijuana was “at least as effective and potentially more effective” than prescription medications for chronic pain, and often accompanied by **reduced opioid use** marijuanamoment.net marijuanamoment.net. Such real-world findings underscore the growing role of cannabinoids (THC, CBD, and others like CBG or

CBN) in managing chronic musculoskeletal pain and improving patients' quality of life.

Epilepsy and Seizure Disorders:

In the realm of severe epilepsy, **cannabidiol (CBD)** has solidified its place as a breakthrough therapy. New clinical evidence (published in early 2025) confirms that the FDA-approved **CBD formulation Epidiolex** significantly reduces seizure frequency in drug-resistant epilepsy norml.org. In a cohort of 208 children with refractory epilepsy, adding CBD led to a **median seizure reduction** from 30 per month to just 8, and nearly half of patients achieved over a 25% decrease in seizures norml.org. About 21% of patients even saw their seizure rates drop by more than 50% norml.org. Researchers concluded that cannabidiol provides meaningful benefits across various epilepsy syndromes beyond the originally approved conditions (Dravet and Lennox–Gastaut syndromes) norml.org. These findings, alongside positive caregiver reports of improved quality of life investor.jazzpharma.com, reinforce the value of medical cannabis in epilepsy treatment. Many countries have followed the U.S. and EU in approving CBD-based medicines for severe childhood epilepsies, and ongoing studies are examining whether other cannabinoids or formulations can further help in seizure management.

Cancer Symptom Relief and Treatment:

The past year saw the largest-ever analysis of cannabis in cancer care, which found broad consensus on its therapeutic value. An April 2025 meta-analysis (reviewing over **10,000** studies) reported “*overwhelming scientific support*” for medical cannabis in managing cancer-related symptoms like **inflammation, nausea, appetite loss, and pain** theguardian.com. About 75% of available studies showed positive effects, a remarkably high agreement in a field long considered controversial theguardian.com. Intriguingly, this analysis – published in *Frontiers in Oncology* – also noted that **cannabis might directly impede cancer progression**, citing evidence of cannabinoids inducing cancer cell death and inhibiting tumor spread in preclinical models theguardian.com.

Small human trials offer hopeful signals: in one pilot with 21 patients on chemotherapy, those receiving a cannabis-based medicine survived longer than placebo patients theguardian.com. Another study in 119 cancer patients found a synthetic CBD analog reduced tumor size and circulating tumor cells theguardian.com. However, oncologists caution that while **cannabis is firmly established for palliative use** (easing pain, anxiety, appetite issues), its **anti-cancer effects in patients remain unproven** without larger clinical trials theguardian.com theguardian.com. The consensus is that more research is needed – something that could be accelerated if legal barriers (such as U.S. Schedule I status) are lifted theguardian.com. Overall, the past year's findings have bolstered the view that medical cannabis can significantly improve cancer

patients' quality of life, with emerging data hinting at disease-modifying potential that warrants further investigation.

Innovations in Delivery and Consumption Methods

Medical cannabis products have diversified, giving patients alternatives to traditional smoking. **Inhalation technologies** saw notable innovation: companies introduced **metered-dose cannabis inhalers** that deliver precise THC/CBD doses, similar to an asthma inhaler. In May 2025, Curaleaf International received EU certification for the first handheld liquid cannabis **inhalation device**, a Class IIa medical device providing consistent, controlled dosing via snap-in cartridges cannabisbusinesstimes.com. Such inhalers allow rapid relief (comparable onset to vaporization) but with pharmaceutical-level accuracy, improving safety. Standard vaporization (using flower or oil vape pens) also remains popular for fast-acting relief, and regulators are encouraging **vapor or inhaler use over smoking** to reduce harmful combustion byproducts.

Oral and edible formulations have become mainstream for sustained symptom control. Cannabis oils, capsules, tinctures, and **edibles** (such as gummies or baked goods) enable easy dosing and longer-lasting effects (4–8 hours). Many patients prefer these forms for chronic conditions. In surveys of medical users, nearly half reported regularly using edibles, oils, or tincture drops as part of their regimen marijuanamoment.net. Oral routes avoid inhalation risks, though they have a slower onset (30–90 minutes) and can be harder to titrate. To address this, sublingual sprays and mouth-dissolving strips are also available in some markets, providing quicker absorption than standard edibles. **Beverages** infused with cannabinoids have even entered the medical market in some regions, offering a familiar consumption method, though dosing consistency can be a challenge.

Topicals and transdermal patches represent a growing niche for localized or steady delivery. Cannabis-infused creams, balms, and lotions are being used for arthritis, neuropathic pain, and dermatological conditions (like psoriasis) without causing systemic effects or a “high.” Researchers are actively developing improved **transdermal patches** that deliver cannabinoids through the skin into the bloodstream. These patches can provide **sustained release** of CBD and THC for up to 12 hours, helpful for managing pain or spasms overnight. For example, proprietary CBD patch formulations are under study for inflammatory skin conditions and have shown promise in early trials by alleviating psoriasis symptoms pmc.ncbi.nlm.nih.gov. While commercial patches (often in 1:1 CBD:THC ratios) are already sold in certain markets, advances in skin-permeation technology are making them more effective. Patients value topicals and patches for avoiding inhalation and minimizing psychoactive effects, though they are generally best for targeted relief.

Emerging methods are also on the horizon.

Pharmaceutical companies are investigating **nasal sprays** for ultra-rapid cannabinoid delivery (potentially useful in seizure rescue or acute pain). Suppositories have been explored for patients who cannot take oral meds. Additionally, the concept of **microdosing** (very low, frequent doses of THC to avoid impairment) has trended, enabled by products like low-dose mints or inhalers that dispense just 1–2 mg per puff. Overall, the past year has seen a trend toward **precision dosing and patient-friendly formats** – moving medical cannabis closer to conventional medicines in delivery, while giving patients more flexibility to find what works best for their condition and lifestyle.

Legal and Regulatory Updates (2024–2025)

Globally, the medical cannabis landscape continues to evolve, with many jurisdictions enacting reforms in the past 12 months. **In the United States**, which has a patchwork of state laws, there were pivotal federal moves. In late 2023, the Department of Health and Human Services recommended that cannabis be rescheduled from Schedule I to Schedule III of the Controlled Substances Act, recognizing accepted medical use. In May 2024, the U.S. Department of Justice formally **proposed a rule** to make this change, opening a public comment process [ncsl.org](https://www.ncsl.org). While cannabis remains federally illegal as of mid-2025, this rescheduling effort – if finalized – would mark a historic shift, easing research restrictions and acknowledging medical value. Meanwhile, at the state level, legalization marches on: as of February 2025, **39 U.S. states (plus D.C.) have legalized medical cannabis** in some form [ncsl.org](https://www.ncsl.org), and several states expanded qualifying conditions or access in the past year. For example, Kentucky and North Carolina took steps toward establishing medical programs, and voters in states like Ohio approved broader cannabis measures that include medical provisions. The U.S. also saw continued legislative debate on issues like banking access for cannabis businesses and allowing VA physicians to recommend cannabis to veterans, reflecting growing acceptance of cannabis therapy.

Europe experienced incremental but meaningful regulatory developments. By 2024, **22 out of 44 European countries** had legalized medical cannabis or cannabis-based medicines, up from virtually none a decade ago [astuteanalytics.com](https://www.astuteanalytics.com). In the past year, France extended its national pilot program for medical cannabis (involving ~3,000 patients) to gather more data before wider approval [astuteanalytics.com](https://www.astuteanalytics.com). Germany – home to Europe’s largest medical cannabis market – not only continued expanding patient access but also drafted plans for adult-use legalization (expected to indirectly reduce stigma and spur medical cannabis investment). Countries like **Ireland and Poland** moved to improve their medical cannabis access schemes, and **Italy** increased import quotas to address patient demand. A notable trend is European regulators standardizing quality: the European Medicines Agency and national authorities issued new guidelines in 2024 on **Good Manufacturing Practice (GMP)** for cannabis cultivation and consistent THC/CBD dosing in products, aiming to treat medical cannabis more like other prescription pharmaceuticals. However, variations remain:

some EU nations (e.g. Sweden, Slovakia) still prohibit medical marijuana, underscoring the region's diverse regulatory patchwork.

In the **Asia-Pacific region**, traditionally strict countries showed some shifts. **Japan** made headlines in December 2024 by passing a dual reform: it **legalized cannabis-derived medicines** (such as CBD-based drugs for epilepsy) under a new licensing system, while simultaneously **criminalizing recreational cannabis use** with harsh penalties [english.kyodonews.net](https://www.kyodonews.net/english.kyodonews.net)english.kyodonews.net. This move – driven by concern over rising youth use – means Japan will allow approved medical cannabis products (imports like Epidiolex are anticipated) for the first time in its history, even as non-medical use remains completely banned. Elsewhere in Asia, **Thailand** continued to solidify its unique position: after decriminalizing cannabis in 2022, it has embraced medical and wellness uses of cannabis, even as its new government in 2024 considered stricter rules to address uncontrolled recreational sales.

Australia, which federally legalized medical cannabis in 2016, saw a **surge in patient numbers** over the last year, accompanied by regulatory scrutiny. By late 2024, Australia was approving around *10,000 medical cannabis prescriptions per week*, and in just July–December 2024, some **441,000 new patients** initiated treatment with high-THC cannabis products [abc.net.au](https://www.abc.net.au). This boom, driven largely by telehealth clinics, prompted Australia's regulator (AHPRA) to launch inquiries into prescribing practices and to ensure patient safety is prioritized over profit [abc.net.au](https://www.abc.net.au)[abc.net.au](https://www.abc.net.au). Overall, the legal trajectory in Asia-Pacific is mixed: a few countries liberalizing medical use, while others like China, Singapore, and Indonesia maintain zero-tolerance policies.

Latin America continues to develop a robust medical cannabis framework. Many countries had legalized medical use in prior years, but 2024 saw refinement of those regulations. For instance, **Argentina** tightened its program rules to improve oversight: a 2024 resolution capped the number of patients per licensed home-grow caregiver and mandated specialized training for doctors who prescribe cannabis [benzinga.com](https://www.benzinga.com)benzinga.com. This was aimed at combating abuses and “re-focusing on the original spirit” of providing safe, research-based patient care. **Brazil** has expanded access through regulatory approvals of high-CBD products – as of 2024, dozens of cannabis-derived medicines (oils and oral solutions) are available via prescription, and patient numbers have grown into the tens of thousands. **Mexico**, despite federal legalization in principle (Supreme Court rulings), is still awaiting formal regulations; however, medical cannabis is technically allowed and imports of CBD remedies continued under permits.

Smaller nations from **Chile and Peru to Jamaica** also reported increasing enrolment in their medical cannabis programs in the past year, often while eyeing the economic benefits of cannabis cultivation. A cross-cutting theme in Latin America has been balancing patient access with UN treaty obligations – several governments in 2024 called for clearer international guidelines as they modernize domestic cannabis laws.

Africa has seen nascent medical cannabis policies, although progress in the last year was gradual. Countries like **South Africa, Lesotho, and Zimbabwe** that permit medical

cannabis cultivation/export are now working on patient access domestically, but large-scale programs are still in early stages. In 2024, **Morocco** began implementing its medical cannabis framework passed in 2021, granting licenses for cultivation intended for medical and industrial use, potentially supplying European markets. These regulatory steps, while regionally important, are in their infancy relative to developments elsewhere.

Global vs. UK: Regional Comparison

To put developments in perspective, the table below compares major regions’ medical cannabis status & recent progress, versus the current situation in the **United Kingdom**:

Region/Country	2024–2025 Developments in Medical Cannabis
United States	Medical cannabis legal in 39 states (plus D.C.) as of early 2025 ^{ncsl.org} . Federal reform is underway – the DOJ began proceedings to reschedule cannabis from Schedule I to III, reflecting accepted medical use ^{ncsl.org} . Continued expansion of state programs (e.g. new or expanded programs in Southern states), and mounting evidence of reduced opioid prescriptions in states with cannabis access ^{marijuanamoment.net} ^{marijuanamoment.net} .
Canada	Nationally legalized (medical since 2001; full adult-use since 2018). The medical program remains intact, but patient registrations are declining as many patients obtain cannabis from recreational outlets. Registered medical clients fell to ~175,000 in late 2024 (down from ~330,000 in 2018) ^{canada.ca} . Health Canada in 2024 affirmed the need to keep a distinct medical access channel, while focusing on product quality and research.
Europe (EU)	Majority of EU states allow medical cannabis in some form (22 of 44 European countries by 2023) ^{astuteanalytica.com} . Germany and Italy lead in patient numbers and imports, while France and Spain run limited pilot programs ^{astuteanalytica.com} . European regulators are standardizing oversight – e.g. EU-GMP standards for growers and moves toward EU-wide recognition of prescriptions. Access varies widely: some countries have thriving programs with thousands of patients, others still tightly restrict usage despite legalization.
Australia	Federally legal for medical use since 2016, with explosive growth recently. In 2024, Australia saw roughly 441,000 new patients start on high-THC cannabis within 6 months ^{abc.net.au} . Over 5,700 healthcare providers have prescribed cannabis. Regulators (TGA/AHPRA) launched reviews in 2025 to ensure responsible prescribing amid the boom. Despite some concerns, the

Region/Country	2024–2025 Developments in Medical Cannabis
	government continues to support access, and low-dose CBD was down-scheduled (to over-the-counter) – though as of 2025 no OTC CBD product is approved yet.
Latin America	Widespread adoption of medical cannabis laws, with ongoing improvements. Colombia, Uruguay, Argentina, Mexico, Brazil and others permit medical use; many also license cultivation. In 2024 Argentina revised its program to tighten controls on growers and require physician training benzinga.com , aiming for safer patient access. Brazil 's health authority approved more cannabis products (totaling 20+ by 2025), and Mexico in theory allows medical cannabis but is working on regulatory clarity. Overall, Latin American nations are positioning themselves as both treatment providers and exporters in the cannabis industry.
Asia	Generally restrictive, but notable exceptions emerged. Japan passed a law (effective Dec 2024) to legalize cannabis-based medicines (e.g. Epidiolex) under a strict licensing regime english.kyodonews.net – a first for the country – even as it criminalized all recreational use. Thailand stands out with a broad medical cannabis program and de facto legalization; however, other Asian countries (China, Indonesia, etc.) still ban medical use outright. South Korea and Malaysia allow only limited cannabis-derived pharmaceuticals. Asia's progress is limited but growing interest in therapeutic cannabinoids is evident.
United Kingdom	Medical cannabis was rescheduled in 2018, but access remains tightly controlled . Only specialist doctors can prescribe, and very few prescriptions are available through the NHS. Instead, a private clinic sector has expanded – by 2025 the UK's medical cannabis market quietly grew to serve over 65,000 active patients per month (via private prescriptions) healthtechdigital.com . Common uses are for chronic pain, anxiety/PTSD, and rare epilepsy (with licensed drugs like Epidiolex). Despite this growth, the NHS has been criticized for minimal uptake , and no major policy liberalization occurred in the past year. The UK is investing in research (e.g. the UK Medical Cannabis Registry is tracking patient outcomes), but compared to North America or Germany, its program is still in an early phase.

References:

Recent medical journals, government health agencies, and reputable news outlets were used to compile the above information. Key references include the *Journal of Psychopharmacology*, *BMJ Psych Open*, *Frontiers in Oncology*, FDA and DEA announcements, Health Canada data releases, as well as news reporting from **The Guardian**, **Kyodo News**, **ABC News (Australia)**, and specialist publications like *Marijuana Moment* and *NORML*[psychiatrist.comabc.net.au](https://www.psychiatrist.com/abc.net.au). These provide an up-to-date and globally representative picture of medical cannabis developments during June 2024–June 2025. The landscape is evolving rapidly, and continued research and policy engagement are anticipated as more jurisdictions recognize the therapeutic potential of cannabis.

Citations



[FDA Approves Cannabis Study for Veterans with PTSD](https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/)

<https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/>



[FDA Approves Cannabis Study for Veterans with PTSD](https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/)

<https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/>



[FDA Approves Cannabis Study for Veterans with PTSD](https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/)

<https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/>



[FDA Approves Cannabis Study for Veterans with PTSD](https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/)

<https://www.psychiatrist.com/news/fda-approves-cannabis-study-for-veterans-with-ptsd/>



[Study: Patients With Post-traumatic Stress And Depression Report Improvements Following Cannabis Therapy - NORML](#)

<https://norml.org/news/2024/03/14/study-patients-with-post-traumatic-stress-and-depression-report-improvements-following-cannabis-therapy/>



Lesser-Known Cannabis Component CBG Linked To Improved Memory And Reduced Anxiety, First-Ever Human Trial Finds - Marijuana Moment

<https://www.marijuanamoment.net/lesser-known-cannabis-component-cbg-linked-to-improved-memory-and-reduced-anxiety-first-ever-human-trial-finds/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Medical Marijuana Helps Most Patients Effectively Treat Chronic Pain, New Study Shows - Marijuana Moment

<https://www.marijuanamoment.net/medical-marijuana-helps-most-patients-effectively-treat-chronic-pain-new-study-shows/>



Study: FDA-Approved CBD Formulation Significantly Reduces Seizure Frequency in Young People With Refractory Epilepsy

<https://norml.org/news/2025/05/15/study-fda-approved-cbd-formulation-significantly-reduces-seizure-frequency-in-young-people-with-refractory-epilepsy/>



Study: FDA-Approved CBD Formulation Significantly Reduces Seizure Frequency in Young People With Refractory Epilepsy

<https://norml.org/news/2025/05/15/study-fda-approved-cbd-formulation-significantly-reduces-seizure-frequency-in-young-people-with-refractory-epilepsy/>



Study: FDA-Approved CBD Formulation Significantly Reduces Seizure Frequency in Young People With Refractory Epilepsy

<https://norml.org/news/2025/05/15/study-fda-approved-cbd-formulation-significantly-reduces-seizure-frequency-in-young-people-with-refractory-epilepsy/>



Jazz Pharmaceuticals to Present New Data Demonstrating Improved ...

<https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-new-data-demonstrating-improved>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Medical cannabis shows potential to fight cancer, largest-ever study finds | US healthcare | The Guardian

<https://www.theguardian.com/us-news/2025/apr/18/medical-cannabis-cancer-study>



Curaleaf International Secures EU Medical Device Certification | Cannabis Business Times

<https://www.cannabisbusinesstimes.com/international/news/15745584/curaleaf-curaleaf-international-secures-eu-medical-device-certification>



[Curaleaf International Secures EU Medical Device Certification | Cannabis Business Times](https://www.cannabisbusinesstimes.com/international/news/15745584/curaleaf-curaleaf-international-secures-eu-medical-device-certification)

<https://www.cannabisbusinesstimes.com/international/news/15745584/curaleaf-curaleaf-international-secures-eu-medical-device-certification>

[Efficacy and Safety of Cannabis Transdermal Patch for Alleviating ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249749/)

<https://pmc.ncbi.nlm.nih.gov/articles/PMC11249749/>

[State Medical Cannabis Laws](https://www.ncsl.org/health/state-medical-cannabis-laws)

<https://www.ncsl.org/health/state-medical-cannabis-laws>

[State Medical Cannabis Laws](https://www.ncsl.org/health/state-medical-cannabis-laws)

<https://www.ncsl.org/health/state-medical-cannabis-laws>



[Europe Medical Cannabis Oil Market Size, Share | Forecast](https://www.astuteanalytica.com/industry-report/europe-medical-cannabis-oil-market)

<https://www.astuteanalytica.com/industry-report/europe-medical-cannabis-oil-market>



[Europe Medical Cannabis Oil Market Size, Share | Forecast](https://www.astuteanalytica.com/industry-report/europe-medical-cannabis-oil-market)

<https://www.astuteanalytica.com/industry-report/europe-medical-cannabis-oil-market>



[Japan criminalizes cannabis use as revised laws take effect](https://english.kyodonews.net/news/2024/12/7c71d582ea2c-japan-criminalizes-cannabis-use-as-revised-laws-take-effect.html)

<https://english.kyodonews.net/news/2024/12/7c71d582ea2c-japan-criminalizes-cannabis-use-as-revised-laws-take-effect.html>



[Japan criminalizes cannabis use as revised laws take effect](https://english.kyodonews.net/news/2024/12/7c71d582ea2c-japan-criminalizes-cannabis-use-as-revised-laws-take-effect.html)

<https://english.kyodonews.net/news/2024/12/7c71d582ea2c-japan-criminalizes-cannabis-use-as-revised-laws-take-effect.html>



[Medicinal cannabis prescribing practices under scrutiny after scripts issued 'every 4 minutes' - ABC News](#)

<https://www.abc.net.au/news/2025-05-19/medicinal-cannabis-ahpra-prescription-boom/105295086>



[Medicinal cannabis prescribing practices under scrutiny after scripts issued 'every 4 minutes' - ABC News](https://www.abc.net.au/news/2025-05-19/medicinal-cannabis-ahpra-prescription-boom/105295086)

<https://www.abc.net.au/news/2025-05-19/medicinal-cannabis-ahpra-prescription-boom/105295086>



[Medicinal cannabis prescribing practices under scrutiny after scripts issued 'every 4 minutes' - ABC News](https://www.abc.net.au/news/2025-05-19/medicinal-cannabis-ahpra-prescription-boom/105295086)

<https://www.abc.net.au/news/2025-05-19/medicinal-cannabis-ahpra-prescription-boom/105295086>



[Argentina Tightens Medical Cannabis Rules: Key Changes For REPROCANN In 2024 And How They Impact Patients - Benzinga](https://www.benzinga.com/markets/cannabis/24/08/40467975/argentina-tightens-medical-cannabis-rules-key-changes-for-reprocann-in-2024-and-how-they-impact-patients)

<https://www.benzinga.com/markets/cannabis/24/08/40467975/argentina-tightens-medical-cannabis-rules-key-changes-for-reprocann-in-2024-and-how-they-impact-patients>



[Argentina Tightens Medical Cannabis Rules: Key Changes For REPROCANN In 2024 And How They Impact Patients - Benzinga](https://www.benzinga.com/markets/cannabis/24/08/40467975/argentina-tightens-medical-cannabis-rules-key-changes-for-reprocann-in-2024-and-how-they-impact-patients)

<https://www.benzinga.com/markets/cannabis/24/08/40467975/argentina-tightens-medical-cannabis-rules-key-changes-for-reprocann-in-2024-and-how-they-impact-patients>



[Data on cannabis for medical purposes - Canada.ca](https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/medical-purpose.html)

<https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/medical-purpose.html>



[The UK Medical Cannabis Market Is Quietly Booming — You Just Didn't Notice - Digital Health Technology News](https://www.healthtechdigital.com/the-uk-medical-cannabis-market-is-quietly-booming-you-just-didnt-notice/)

<https://www.healthtechdigital.com/the-uk-medical-cannabis-market-is-quietly-booming-you-just-didnt-notice/>



[psychiatrist](#)



[norml](#)



[marijuanamoment](#)



[investor.jazzpharma](#)



[theguardian](#)



[cannabis...nesstimes](#)

[pmc.ncbi.nlm.nih](#)

[ncsl](#)



[astuteanalytica](#)



[english.kyodonews](#)



[abc.net](#)



[benzinga](#)



[canada](#)



[healthtechdigital](#)